稳定币也能结合 AI?详解 USD.AI 新玩法

marsbitPublished on 2025-08-19Last updated on 2025-08-20

根据Coingecko数据显示,当前全球稳定币市值已超过2850亿美元。而Circle、Kraken等巨头也在纷纷踏入稳定币支付链赛道。

然而,当前绝大多数稳定币项目仍以锚定美元、美债等传统模式为主,整体创新型略显不足,普遍“缺乏想象力”。在这样的背景下,一个与众不同的挑战者正以全新姿态闯入市场。

近日,一个独特融合DePIN、RWA和AI的稳定币项目USD.AI,引发市场热烈讨论。它不只是简单锚定美元,而是通过AI硬件抵押生成收益,填补了计算资源融资的空白。

DeFi

而就在今日早间,USD.AI正式上线并开启存款通道,热度迅速窜升。这有可能带来AI-稳定币融合的新机遇。


项目背景

根据 Rootdata 数据显示,该项目于2024年成立,项目团队方面,USD.AI的核心创始人之一David Choi是知名NFT借贷平台MetaStreer的联合创始人兼CEO,此前曾是Deutsche Bank投资银行分析师。

真正将USD.AI推向聚光灯之下的,是其引人注目的融资背景。

本月14日,USD.AI 宣布完成1340万美元A轮融资,由Framework Ventures领投。

作为一家专注于DeFI和基础设施的投资机构,Framework Ventures曾支持过Uniswap和ChainLink等明星项目,此次参与领投USD.AI,也反映出机构对该项目创新价值的认可。其他投资方阵容同样强大,有知名加密VC Dragonfly,Layer2网络巨头Arbitrum以及刚刚完成IPO上市的热门交易所Bullish等。

DeFi

此轮融资的豪华阵容不仅为USD.AI注入了雄厚资源,也验证了DePIN结合AI的稳定币项目对顶级资本的吸引力,显著提高了市场对其的预期。而在融资信息发布过后,USD.AI项目方趁热打铁,于19日正式上线,引发了市场的广泛讨论。


运作原理与核心机制

在AI算力需求增长的背景下,USD.AI 的设计是将稳定币协议与AI基础设施融资相结合,来解决当前市场上其他项目没有涉足的问题:

中小型AI公司拥有价值高昂的GPU硬件,却难以通过传统渠道获得运营资金。

项目核心目标是通过链上资本支持AI公司硬件采购和运营,填补传统金融在新型AI经济中的融资空白,同时保持稳定币的低风险特性。

USD.AI 围绕“抵押-铸造-投资-收益”这一闭环系统,结合当下热门的RWA与AI概念,在这一轮稳定币浪潮中展示了其独有的创新优势。

USD.AI的运作原理始于用户以USDT或USDC等稳定币作为抵押品,按1:1比例铸造USDai稳定币。USDai由美国国债和主流稳定币支持以达到锚定美元价格并具有即时赎回能力和一定的流动性,适合DeFi生态中的交易或提供流动性,同时用户可以进一步选择质押USDai获取sUSDai代币,再参与其他DeFi项目获取额外收益,达到“一鱼多吃”的效果。

USD.AI将用户存入资金用于两类资产投资:一是向AI公司提供贷款用于采购GPU等硬件,生成高额利息,当前官网显示年化收益率为6.96%;二是若资金闲置将被用于投资美国国债,提供稳定基础收益。sUSDai持有者可通过DeFi协议放大收益,项目官网给出的目标年化收益率达15%-25%,而USDai持有者则享受低风险稳定收益。

DeFi

USD.AI核心机制包含以下几个关键组成部分,以确保其创新性和稳定性:

1.双代币系统:USDai作为低风险稳定币,适合追求稳定性的用户;sUSDai则面向寻求高收益的投资者,兼具灵活性和风险敞口。这种设计满足不同风险偏好的用户需求,同时保持DeFi生态的兼容性。

2.资产代币化与Caliber框架:通过CALIBER框架,USD.AI将Ai硬件等物理资产代币化为链上资产,结合法律和技术手段确保资产所有权透明且具有法律约束力。链上保险机制进一步降低违约风险。

3.QEV赎回机制:为应对AI基础设施资产的长期性和低流动性,USD.AI设计了QEV机制,通过市场驱动的方式管理sUSDai赎回请求,避免先到先得的低效性,同时确保协议的公平性和协议稳定性。

4.FiLo Curator扩展机制:这一机制允许协议大规模引入新借款人,扩展Ai基础设施投资组合,同时通过结构保护和风险对齐机制维护用户利益,确保收益来源的多样性和可持续性。

总结来说,用户存入USD.AI的资金将被用于贷款给需要GPU等硬件设备算力的AI公司来获取利息,全程透明可查,若资金闲置将用于购买美国国债获取保底收益。

USD.AI的创新机制使其具有独特的竞争优势,相较于传统稳定币项目,USD.AI通过AI基础设施投资实现更高收益;与高风险DeFi协议相比,其风险隔离和保险机制显著降低了系统性风险。

USD.AI此番不仅为稳定币市场注入了新活力,也为Ai经济的资本需求提供了可扩展的解决方案,有望成为稳定币与Ai基础设施融合的先锋项目。


参与方式

目前USD.AI项目已经开放用户存款以及邀请其他用户以获取USD.AI奖励系统Allo积分。

用户可以通过ICO和空投两种方式获得最终代币奖励。所有参与者都将以3000万美元流通量(对应总FDV3亿美元的10%)的项目估值进入。

根据官方推文显示,铸造或质押USDai将会在后续每天持续产出积分,用户可以选择不同的策略决定自己最终获得ICO配额或者空投奖励。

Allo积分活动将会在YPO(累计已支付收益)达到2000万美元时结束。选择ICO配额的用户需要通过KYC,而选择空投的用户则无需过KYC。

更多Allo积分获取进阶玩法可以通过官方推文中的介绍视频了解。

DeFi

简单来说,若想要参与项目ICO,持有USDai即可,若想参与空投则需要将USDai质押获取sUSDai。

当前购买USDai或sUSDai将获得qUSDai,qUSDai为存款排队证明,将会在24小时内自动转为对应代币。

USD.AI目前总存款上限为1亿美元,由于当前所有购入资金均处于qUSDai状态,所以当前TVL仅显示为内测期间存入的5200万美元。

DeFi


市场讨论

当前市场对USD.AI项目的看法呈现两极分化。

支持的用户普遍认为USD.AI是具有独特创新的稳定币项目,并且结合了当前热门AI概念,让用户可以在保证稳定收益的同时享受到AI红利。给出多种参与策略让不同类型的用户都可以找到适合自己的方案,兼具了稳定币的“稳定”特性的同时还给出了高风险高收益的选择。

DeFi

而持反对观点的用户则认为,USD.AI目前披露的信息显示其团队背景可能以华人为主,并且项目只是简单堆砌热门概念,缺乏实质创新。

DeFi

有趣的是,USD.AI核心创始人David刚刚在这条FUD推文下进行了回复,称自己为韩裔美国人,同时表明项目总部位于纽约,但非常乐意为中文用户答疑解惑。

DeFi

笔者认为,USD.AI确实是给出了稳定币这个热门赛道不一样的答卷,但是否能获得市场的青睐与认可,还需要看大家是否愿意“用脚投票”快速打满一亿美元的TVL上限。

其成败与否,也将成为衡量市场对“AI基础设施+稳定币”这一新兴叙事接受度的试金石。

Trending Cryptos

Related Reads

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

On August 18th, Haowei Huaxin, a semiconductor firm specializing in gallium arsenide and gallium nitride wafers, reported that over a hundred individuals forcibly entered its offices and seized the company's official seals from a safe, including the corporate, contract, and party committee seals. The incident is the latest escalation in a protracted control dispute. Haowei Huaxin, established in 2010, was originally a joint venture. Control became contested after 2021 when Zhenwei Financial Holding injected capital, becoming the largest shareholder (34.01%), while former parent Haite High-Tech's stake was diluted to 33.79%. An agreed-upon governance structure collapsed, leading to mutual accusations. Haite claimed it was locked out of the subsidiary's premises, while also alleging improper management like livestock being kept on the chip fabrication site. After state-owned Qingdao Haiyue Holdings took over Zhenwei's stake in 2023, Haite accused it of illegally seizing control. Despite Haite winning several legal battles in 2024-2026, which affirmed its rights to nominate directors and the chairman, it failed to regain physical control or recover the seals. The stakes are high: market valuations for Haite's stake in Haowei Huaxin are estimated between 3.7 to 5 billion USD, yet it is only valued at about 83 million USD on Haite's books. Losing control effectively jeopardizes a significant portion of Haite's value. In response to the seal seizure, Haite framed it as a "shareholder rights protection" action agreed upon by five shareholders. This mirrors a pattern in Chinese corporate disputes where seizing physical seals becomes a tactic to paralyze the opponent's daily operations, seen in past conflicts at companies like Dangdang and Bitmain. However, such actions don't resolve underlying ownership issues; the opposing party can report the seals stolen, declare them void, and apply for new ones, albeit with significant delay. The incident underscores how fragile corporate governance can devolve into physical confrontations over symbols of authority, with control ultimately determined by law and shareholding, not possession of a seal.

marsbit34m ago

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

marsbit34m ago

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

Bernstein's analysis of Moderna's 177% stock surge following positive Phase 3 results for its individualized neoantigen therapy (INT) in melanoma distinguishes fundamental drivers from market speculation. The clinical breakthrough is real: the INTerpath-001 trial met its primary and key secondary endpoints, providing crucial validation for mRNA technology in oncology beyond infectious diseases. However, Bernstein argues the magnitude of the stock move cannot be justified by this single trial's fundamentals alone. The surge was amplified by three key factors: 1) A re-rating of Moderna's mRNA platform potential for expansion into other cancers, 2) A massive short squeeze, given ~15% of shares were sold short pre-announcement, and 3) The compelling "cancer vaccine" narrative that fueled broader investor enthusiasm. While the melanoma success is significant, Bernstein cautions that replication in lung, kidney, and bladder cancers—which have different immunogenicity—is not guaranteed. Furthermore, INT's commercial model faces challenges: it's a personalized treatment, not a mass-market vaccine, implying higher production costs and potential margin pressures despite a projected multi-billion dollar peak sales opportunity. The report also notes sector rotation, with some funds moving from crowded AI/semiconductor trades into defensive healthcare stocks, adding further momentum. In conclusion, Bernstein maintains a "Market-Perform" rating and a $45 price target, far below the post-surge price. It views the current valuation as pricing in an optimistic multi-cancer platform success and efficient commercialization that are yet to be proven. The clinical inflection point is clear, but the earnings inflection point awaits validation across future trials and commercial execution.

marsbit35m ago

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

marsbit35m ago

Trading

Spot

Hot Articles

Discussions

Welcome to the HTX Community. Here, you can stay informed about the latest platform developments and gain access to professional market insights. Users' opinions on the price of AI (AI) are presented below.

活动图片